Seres Therapeutics, Inc. (NASDAQ:MCRB) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

A number of other equities analysts also recently issued reports on the company. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a research report on Wednesday, July 5th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research report on Friday, May 19th. Cantor Fitzgerald set a $16.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 4th. Finally, ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 1st. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $16.17.

Seres Therapeutics (MCRB) traded down 0.82% during mid-day trading on Friday, hitting $13.35. The company’s stock had a trading volume of 25,390 shares. The firm’s 50-day moving average is $12.49 and its 200-day moving average is $10.66. Seres Therapeutics has a 12-month low of $8.85 and a 12-month high of $15.09. The company’s market cap is $540.84 million.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. The business had revenue of $3 million for the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business’s revenue for the quarter was up .0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.70) earnings per share. Analysts predict that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.

WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.watchlistnews.com/seres-therapeutics-inc-mcrb-downgraded-by-bidaskclub-to-hold/1472401.html.

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the last quarter. State Street Corp increased its position in Seres Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 275,970 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 16,671 shares during the last quarter. Citadel Advisors LLC increased its position in Seres Therapeutics by 74.8% in the first quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 8,841 shares during the last quarter. Highbridge Capital Management LLC increased its position in Seres Therapeutics by 104.0% in the first quarter. Highbridge Capital Management LLC now owns 30,843 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 15,726 shares during the last quarter. Finally, Spark Investment Management LLC purchased a new position in Seres Therapeutics during the first quarter valued at about $613,000. 75.31% of the stock is currently owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.